

Annual Review

& Financial Statements

1 Apr 2019 – 31 Mar 2020



THE COMMON VOICE FOR
RARE & LESS COMMON CANCERS

Contents

LET'S MAKE SOME NOISE	3	MONEY TALKS – financial review	23
		Financial statement	23
		Reserves policy	23
STRENGTH IN UNITY	4	INDEPENDENT EXAMINERS' REPORT TO THE TRUSTEES OF CANCER52	24
Who we are and what we stand for	4	Respective responsibilities of the trustees and the examiner	24
Our core principles	4	Independent examiners' statement	25
		Section A: Statement of financial activities including summary income and expenditure account	26
UNITING WITH ONE VOICE	6	Section B: Balance sheet	27
Cementing the alliance	6	Section C: Notes to the accounts	28
The Cancer52 team	6	1 Basis of preparation	28
Our charity members	7	2 Accounting policies	30
Member engagement	8	3 Income	32
		4 Analysis of expenditure	33
MAKING OURSELVES HEARD	9	5 Details of certain types of expenditure	33
Working methods	9	6 Creditors and accruals	34
Member interaction	9	7 Cash at bank and in hand	34
Representation	10	8 Fair value of assets and liabilities	35
Media and digital platforms	12	9 Charity funds	36
Collaboration	13	10 Transactions with trustees and related parties	38
Adapting to the challenge of COVID-19	14	Administrative details	41
		Cancer52 – List of charity members	42
SEAT AT THE TABLE	14		
Achieving a national commitment to early diagnosis	15		
Achieving the highest-level representation	15		
Achieving a broader recognition among influential people in the field	15		
Looking forward	17		
OUR SUPPORT	18		
The value of our support	18		
Support from industry	18		
Voluntary member donations	19		
Trusts and individual donations	19		
THE ACOUSTICS	20		
Structure and governance	20		
Purpose	20		
Public benefit	21		
Board and management operations and structure	21		
Risk assessment and management	22		

Let's make some noise

I have great pleasure in writing this foreword for our 2019-20

Cancer52 Annual Review. Cancer52 is a unique organisation and we have grown over the years from a loose alliance to a more focussed and cohesive charity that pulls together the voice of rare and less common cancers and onwardly transmits it.

I have been Chair of Cancer52 for five years and I am proud to see the way the organisation has evolved in that time, and would like to thank my fellow trustees and all our member organisations for their work in encouraging Cancer52 onwards.



Jonathan Pearce, Chair

Welcome to our Annual Review 2019-20

It's being written at an unprecedented time, about a time we then thought was challenging, which made us think hard about the best role we could play as Cancer52. The answer in the financial year to end March 2020 was to ensure that we achieved a presence in the highest echelons of decision making for those who drive policy for people with rare and less common cancers.

We did well at that with the aim of contributing to the development and delivery of the NHS Long Term Plan for Cancer, with seats on various boards and taskforces, and an advisory or contributory role for other forums. We built our policy presence and brought together the voice of rare and less common cancers better and took it onwards.

As we all now know those steady and planned days were replaced virtually overnight with a new and scary world in which we needed to deliver on our objectives of information sharing and empowering our charity members at lightning speed. We were lucky in one sense – we were already an agile, virtually run organisation with limited overheads and an income to match. We were also lucky in that we had established networks, many of whom we turned to for help, and many of whom we have managed to support over the past months.

We thank all those who helped us build to the structure we achieved by March 2020, and those who have worked so hard alongside us to deliver for one and all since then. Collaboration with member charities, with individuals within those charities and so many colleagues across the NHS and industry have all made bonds that will help deliver on a stronger future for those with rare and less common cancers.



Jane Lyons, CEO

Strength in unity: our principles

Who we are and what we stand for

In 2006, Professor Sir Mike Richards CBE, then National Cancer Director, founded Cancer52 to provide one collaborative voice for people with a rare or less common cancer and to inform the development of the original Cancer Reform Strategy. The name 'Cancer52' was chosen because at that time 52% of cancer deaths were as a result of rare and less common cancers. Things have changed – and not for the better.

Our core principles

We at Cancer52 are an alliance of charitable and not-for-profit organisations, a unifying body providing one representative voice to champion earlier diagnosis, better treatment and stronger support for those with rare and less common cancers. Outside the big four of breast, bowel, lung and prostate, cancer care remains under-represented and under-funded across all areas, including policy, services and research. Our aim is to work towards a point at which there is no longer a discrepancy between the mortality rates of less common cancers and of the big four.


We were registered as a charity in September 2017 and now represent almost 100 mainly small, patient support group cancer charities and organisations united by their vision of seeing a better future for everyone affected.

We are the only influencing organisation solely focused on rare and less common cancers and are passionate about addressing the inequalities faced by people with such a diagnosis. We intend to build on our work so far and take the next steps in developing the organisation so that it can achieve its vision and strategic objectives.



'Cancer52 plays an invaluable role in linking up a large number of small charities, all of whom have a common interest in improving the outcomes for patients with the types of cancer that are at risk of being neglected.'

Alan Moss, Chair, Action Against Heartburn



IN ENGLAND IN 2020

47% of cancers diagnosed are for rare and less common cancers, yet now 55% of deaths are for those cancers¹

Our aim

Our primary aim is to promote improved diagnosis, treatment and support for those affected by rare and less common cancers.

Our vision

Our vision is to see an end to the inequalities in diagnosis, treatment and patient outcomes experienced by those with these challenging diseases compared with the four most common cancers.

Our mission

Our mission is to provide a strong, unified voice for rare and less common cancer organisations by representing, speaking, informing, sharing and involving our members to achieve our vision.

Our values

Everything we do is underpinned by our values, which are to be:

ambitious | outcomes-focused | collaborative
evidence-based | influential
and to behave with honesty and integrity.



'As a small charity, the LSN values the opportunity to work with the other members of Cancer52 to ensure that the needs of those affected by rare and less common cancers and the side-effects of treatment continue to have a voice in the wider cancer community.'

Karen Friett, Chief Executive,
Lymphoedema Support Network



Uniting with one voice:

Cementing the alliance

The intention in creating **Cancer52** was that as an umbrella organisation we could unite the voices of smaller charities from across the UK, but predominantly in England where the bulk of our work is focused. By doing so, we could create a relationship in which we would benefit from access to the knowledge and expertise of our members and, by bringing them together into one unit, be able to better represent their opinions and experiences. This was and remains our core ambition.

Together, we are stronger.

Each charity has valuable expertise and experience; when networked together, they benefit from each other. As a central focus, we are their united voice. Informed by our member organisations, we can bring that voice to bear at a national level and influence national policy and decision makers.

RIP Ingrid Copperman

Ingrid was an integral part of the Cancer52 team for five years until she died in February 2019 of a less common cancer. We commemorated her work in all that we did during the course of 2019. She was much loved and is much missed.



© Marcus Jamieson-Pond jampondphotography.com

who we are


The Cancer52 team

Everything about **Cancer52** is flexible and adaptable, including our administrative team. Our passion for the work we do imbues us with the persistence and determination we need to unite our membership of charities into a group that can wield power and influence. We work under the auspices of the trustees, who are also Board members.

During the year ending 31 March 2020, our team at **Cancer52** consisted of:

- **Jane Lyons, CEO:** responsible for the overall running of the charity
- **Elisa Duriavig, Executive Assistant:** Supporting the CEO as executive assistant, co-ordinating diaries/external meetings with various working groups, liaising with member charities via newsletters, members' meetings and our website
- **Ainsley Taylor, Administrative Specialist:** supporting the CEO on governance, fundraising applications, administration and co-ordination of Trustee recruitment, membership donations and data

We also have consultants who work with us on policy issues and financial administration. Laura Thomas and Jennifer Mitchell from Brighter Together work with us on briefing, policy and reporting and have contributed hugely to our increased profile in this sector; and Jason Dennis who runs our finances for us so efficiently. Our thanks to all of them for their work.



'We're none of us as smart as all of us. It is so important that Cancer52 is there to support us and together we can achieve so much more when campaigning for the bigger picture.'


Helen Bulbeck, Director, Brainstrust

Our charity members

All our charity members work in the field of rare and less common cancers – that is, outside the 'big four' cancers of breast, bowel, lung and prostate. Many are also active in research. They share a determination to work for the needs of their particular patient group in order to bring them in line with the big four in terms of patient outcomes.

Our membership profile is made up of largely small-scale but dedicated organisations:²

- the majority of our member organisations work with rare cancers (identified as those with an incidence of less than 6 per 100,000 persons per year)³
- they are mainly small, patient support group charities, with strong patient involvement
- only a quarter of our members have an income of more than £1 million
- almost half of our members have an income of less than £250,000
- almost all Cancer52 members offer patient support
- two-thirds of our members spend money on research
- over half our members offer patient support and fund research





Making ourselves heard: our methods




Member engagement

We have an active membership who value our passion and commitment and, having joined, tend to remain with us year on year. Two-thirds attended at least one All Member Meeting in 2019–2020, with half attending on more than one occasion. Many people from member charities also gave their time and energy to sit on one of **Cancer52's** working groups.

In the financial year 2019–2020, nearly 300 individuals from member charities attended All Member Meetings or Annual Stakeholder Briefings and a further 100 attended one of our working group meetings during the course of the year.

While the London location for most meetings has prevented some members from attending in person in the past, attendance at meetings increased with the introduction of more virtual events towards the end of 2019–2020, due to the Covid-19 situation. We will continue with virtual events in future years.

Our membership value our passion and commitment.



56 out of 90 member charities attended events / engaged with us in 2019 (62%) **45 out of 90 member charities attended events / engaged with us multiple times in 2019 (50%)**



Working methods

We work tirelessly to promote the needs of people with rare and less common cancers. We have a strong presence in the rare and less common cancer community, being represented at the highest level on boards and task forces.

Close teamwork is a keynote of how we work at **Cancer52**, and our flexible structure allows us to utilise a range of skills and methods to benefit our members and work towards achieving our objectives. From telephone conversations and surveys to seats on influential national cancer bodies, we carefully select the most efficient and effective ways to spread our message.

Member interaction

We interact regularly with our members both at the meetings we organise and through email and information bulletins. Collectively and also as their representatives, we are in constant communication with members of other charities, NHS professionals and administrators, and anyone who has influence in the cancer field.

SHARING: Sharing information empowers members to achieve more both individually and collectively as we share best practice and support each other. For example, many of our member organisations have limited resources so can benefit from research carried out by other member charities. We constantly encourage communication between them and us to keep the information flowing around the group. We use all our contacts and networks to keep in touch, to gain information and to spread information that will forward our cause.

CANCER52 ALL MEMBER MEETINGS: These quarterly meetings were held in London during this financial year but on 23 March 2020 it was announced that they would be virtual until further notice. Whether in a physical or virtual context, they present both our team and our members with ideal networking opportunities, while also offering the chance to listen to some interesting and thought-provoking speakers.

CANCER52 ANNUAL STAKEHOLDER BRIEFINGS: Our Stakeholder Briefings are held annually and provide a great opportunity for all our members to engage with senior level speakers and industry representatives.



'Many thanks for the excellent work you do, facilitating co-operation between the assorted rare cancer charities, and thereby amplifying our voice.'

Terry Weldon, GIST Cancer UK

CANCER52 POLICY AND PUBLIC AFFAIRS STEERING GROUP: A group of members, including our policy team of Brighter Together, the PPASG met quarterly to exchange information and help formulate the policy asks for **Cancer52**. During 2019–2020 this group was chaired by Rebecca Rennison, then of Target Ovarian Cancer.

CANCER52 ACCESS TO DATA WORKING GROUP: Accessing data that helps members plan their campaigns and services is an ongoing challenge for those organisations representing cancers affecting smaller numbers of people. This group, made up of **Cancer52** members, was originally set up to help charities confront this challenge and was well rewarded by Public Health England (PHE) through their Get Data Out initiative, which has greatly improved this access. The **Cancer52** Access to Data Working Group met quarterly this year, chaired by Sarah McDonald, then of Sarcoma UK.

CANCER52 NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) GROUP: This group is convened periodically when there are issues that impact across a number of **Cancer52** members, usually around the topic of patient involvement in any NICE processes. Again, comprising members of **Cancer52** with an interest in the topic, this group meets when there is a specific issue to address.

It is important to note that whilst engaging fully with NICE on broader issues, **Cancer52** does not engage in individual drug appraisals.

A strong and determined alliance, we can make more noise about the need for improvements in cancer services.

Representation

When member charities come together under the **Cancer52** umbrella, we represent them at the highest level and act as a conduit to organisations that need to hear the patient voice of people with rare and less common cancers. As a strong and determined alliance, we can make more noise about the need for improvements in cancer services, including those for people with rare and less common cancers.

In order to deliver the NHS Long Term Plan (LTP)⁴ for cancer, people and partners were brought together to oversee, advise on and implement the programme. The governance structure⁵ is designed to:

- increase transparency and ensure that the cancer community is kept informed
- increase involvement of interested parties in the delivery plan
- build on the positive engagement from the cancer community

During 2019–2020, **Cancer52** was invited to sit on five NHS England boards and groups including:

NATIONAL CANCER BOARD: Alongside Cancer Research UK and Macmillan Cancer Support, we have a place on the National Cancer Board, which is charged with providing strategic leadership across the healthcare sector in the delivery of the cancer ambitions in the NHS LTP.

RAPID DIAGNOSTIC CENTRES' TASK AND FINISH GROUP: This task and finish group was established in May 2019 to inform the development of the Rapid Diagnostic Centre (RDC) model and roll-out across the NHS. RDCs bring together the latest diagnostic equipment and expertise and focus on diagnosing cancers, such as blood and stomach cancers, where patients often present with non-specific symptoms and may go to their GP many times and be sent for a range of tests before diagnosis.

WORKFORCE TASK AND FINISH GROUP: This task and finish group was established in August 2019 to identify, prioritise and take action to address challenges encountered by the NHS workforce. It also advises on the cancer workforce required to deliver the NHS LTP and informs the development of the NHS People Plan.

CANCER PATIENT EXPERIENCE SURVEY ADVISORY GROUP: We sit on the main group and also on the reporting and special projects sub-groups to advise on the Cancer Patient Experience Survey.

NHSE CHARITY FORUM: This forum acts as a conduit to many charities to ensure they are involved and aware of the broader discussions going on in the field of cancer care. It remains cross disciplinary and more widely inclusive of charities than the National Cancer Board.



OTHER INFLUENTIAL GROUPS: **Cancer52** also participates in:

- **Ministerial round tables:** We have a strong relationship with the cancer ministers and are grateful for their support. We also maintain a presence across All Party Parliamentary Groups and engage with MPs interested in the field.
- **CEO charity round tables:** We work with other leading cancer charities with public policy positions under the banner of One Cancer Voice, an alliance of cancer charities. One Cancer Voice worked to produce a cross-cancer manifesto for the General Election of December 2019 and initial guidance for charities to share with their patient groups regarding Covid-19.
- **Public Health England Cancer Stakeholder Group:** We work with other organisations on the co-ordination of this group. This is an advisory group to support the PHE cancer team's work on programmes and conferences.

Media and digital platforms

Speedy communication is vital to our networking model, so we make constant use of the technologies available to disseminate information to our members, communicate with the various cancer bodies and collect and collate useful data and information.

Regular members' ebulletin


This is distributed regularly to our members and includes updates on all aspects of our work. During most of the year to 31 March 2020, our bulletins were distributed two to three times a month; however, during March 2020 – as a result of the Covid-19 pandemic – we increased the frequency to keep up to date with the changing developments as they affected our members.

The bulletins provide information on:

- dates and details of **Cancer52** meetings and meetings by member charities or national organisations
- anything we believe is of relevance to our members
- patient surveys
- NHS and other cancer charity webinars
- developments in NHS strategies, such as the NHS Long Term Plan
- news and events, including updates on the Covid-19 situation from February 2020

Members value the bulletins as providing a useful and efficient way of disseminating information and enabling them to keep in touch with events, activities and developments of which they may otherwise not be aware.

SURVEYS: We research and publish reports into ways of achieving our objective of improving the lives of people with rare or less common cancers, collating information from our membership to heighten their presence within the debate.



In 2019–2020, we were delighted to achieve an annual opening rate of almost half (46.1%) and an impressive click-through rate of 12.4%.

76% of subscribers are highly engaged in our e-bulletins and often open and click-through on our emails.

Website

We maintain a website as a central point for information for both members and a broader audience. The key message is that we need to spend more time, money and effort on coping with rare and less common cancers so that the patient experience, treatment and outcomes can be improved.

The site includes links to all member organisations, sponsors and the groups we collaborate with to help deliver our objectives, making it a useful portal for sharing information between members. It posts reports on our activities and the issues high on the discussion agenda to inform our members and encourage them to engage.

It also makes all our reports available for download, together with informative videos, announcements of upcoming conferences or meetings, contact and donation opportunities.

MEDIA: We respond to media interest but do not actively seek it. However, we are quoted in a recent NHS press release on the introduction of tumour agnostic drugs.⁶ We were also interviewed for a feature by a magazine called *Rare Revolution*,⁷ a digital magazine focused on rare diseases.

SOCIAL MEDIA

We are active on Facebook
en-gb.facebook.com/Cancer52org
and Twitter
[@Cancer52org](https://twitter.com/Cancer52org)
(with almost 2,000 followers), distributing new information, reacting to events and communicating with our members.

VIDEO: Short videos, such as those posted on our website and Facebook pages, disseminate information clearly and quickly and are often reposted so they can reach a wide audience.

Collaboration

We also worked closely with a number of other organisations within the UK cancer community where it helped us deliver on our objectives.

In 2019–2020, we collaborated with:

- **ABPI Patient Organisation Forum:** The Association of the British Pharmaceutical Industry holds quarterly meetings of its Patient Organisation Forum. With other charities, we are invited by the ABPI to join these quarterly briefings and we sit on the steering group that exists to plan the content of the meetings and organise appropriate speakers.
- **Access to Cancer Medicines Coalition:** An umbrella group of 24 charities focused on ensuring that cancer patients have timely access to the most effective medicines.
- **Charity Medicines Access Coalition:** An umbrella group of charities working to find a long-term solution to the challenges that can delay or prevent access to new and innovative medicines. We have an observer role on this group and use this to inform our work on access to medicines.
- **Children and Young People Coalition:** A group that promotes the well-being of younger cancer patients. We sit on the steering group and support the work of charities concentrating on these particularly rare cancers.
- **MHRA Patient Engagement Group:** The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency sponsored by the Department of Health and Social Care. It is responsible for regulating medicines, medical devices and blood components for transfusion in the UK. MHRA seeks input from patient support groups and alliances like **Cancer52** on their engagement and communication with patients. **Cancer52** sits on the engagement group, attending briefings and advising on engagement.
- **National Voices:** A wide-ranging coalition of healthcare charities. We are members and engage where topics are particularly relevant to people with rare and less common cancers.
- **Specialised Healthcare Alliance:** Campaigning on behalf of those with rare and complex conditions. We are a member and attend quarterly briefings on wider topics affecting people with rare cancers.
- **Union for International Cancer Control:** Leading the global fight against cancer. We were a member of the UICC and benefited from engagement with this global effort to beat cancer.
- **Use MY data:** Educating and harnessing the patient voice to understand aspirations and concerns around the use of data in healthcare delivery, we interact with this group to share information and seek help and input from the usemydata team.

Adapting to the challenge of Covid-19

As a tightly knit, flexible and remotely managed organisation, our existing structure was well placed to adapt its business model when the Covid-19 pandemic hit the UK in early 2020. Having already established methods of bringing people together, sharing information and facilitating productive networking in a virtual scenario, we were able to react swiftly to make the adjustments necessary to cope with the essential restrictions.

These involved:

- reprioritising our work to recognise the immediate increase in demand for our support
- reorganising all meetings to virtual ones
- increasing the number of ebulletins to our members
- regularly joining teleconference calls with NHSE and other charities on the evolving situation to ensure an up-to-date flow of accurate and consistent information to our members

These measures continue as we adapt to changing circumstances.

As a flexible and remotely managed organisation, we were well placed to adapt to the Covid-19 pandemic.

A seat at the table: our headline achievements for 2019–2020



Achieving a national commitment to early diagnosis

The NHS Long Term Plan for cancer was published on 7 January 2019.⁴ Our immediate response was published the same day⁸ and we subsequently created a more detailed and informed response.

The importance of the Long Term Plan for this report on 2019–2020 is that it informed our headline objectives for this year and beyond. Most significantly, we asked for a system wide target that included rare and less common cancers as a critical element.

There are two key targets for the cancer programme, the first of which is that by 2028, 75% of all cancers be diagnosed at an early stage (stage 1 or 2). The current figure is 54%.

The significance of this key national target being introduced represents a huge achievement for Cancer52 and its member charities because it will be impossible to achieve this goal unless the rates of early diagnosis of rare and less common cancers are improved substantially to bring them in line with the more common cancers.

We were delighted to see it as a central tenet of the Long Term Plan.

'We would like to make a donation to Cancer52 as a gesture of our real appreciation for the work you are doing on our behalf, we are very grateful and happy to support in any way we can. I know I speak on behalf of all of us here at the Kidney Cancer Support Network.'

Rose Woodward, Kidney Cancer Support Co-founder, patient and advocate



Achieving the highest-level representation

Our other asks of the NHS Long Term Plan related to a presence for rare and less common cancers within governance structures and the new Cancer Alliance structure.

- We gained a seat on the National Cancer Board, the most senior level structure including charity representation.
- We also have seats on the Workforce Task and Finish Group and the Rapid Diagnostic Centre Task and Finish Group.

Both are critical elements for delivery of the Long Term Plan. The Rapid Diagnostic Centres could play a vital role in ensuring swifter and more accurate diagnosis for rare and less common cancers, where symptoms can be less specific than those that are better known, like lumps, or bleeding. Initial findings are supportive of a good rate of diagnosis for some of the rare and less common cancers with serious but non-specific symptoms.

Achieving broader recognition among influencers in the field

Cancer52's round table event on 4 April 2019 involved key thinkers and leaders across the cancer community, and we were delighted to welcome David Fitzgerald, Programme Director of the NHS Cancer Programme, as well as key representatives from the Association of British Pharmaceutical Industries, NICE, the South East London Cancer Alliance and fellow cancer charities.

The subsequent report of the roundtable included input from a member survey, and the insight from this discussion-informed policy thinking and helped maintain NHS focus on these cancers as implementation plans for the NHS Long Term Plan are developed.

NICE Methods Review Patient Group Meeting

On 3 March 2020 we hosted a meeting with our members on the NICE review of methods for health technology evaluation programmes.

This meeting was convened to provide interested charity members with an opportunity to gain insight into how they can engage with the review and discuss priorities and opportunities within its scope.

More than a dozen charity members attended, and a summary of findings and later response to NICE was produced as a result of this meeting.

We had particular support from member charities Leukaemia Care and Sarcoma UK for this event, for which we are grateful.



Data conference focused on rare and less common cancers

We became the first external partner to work with PHE and the National Disease Registration Service to jointly host a one-day data event on 22 May 2019. The theme of the event was improving the patient experience and outcome for people with rare and less common cancers, and we would like to thank Lindsey Bennister, **Cancer52** Trustee, for taking the chair so effectively. We were delighted that the meeting was rated as excellent or good by 100 per cent of the almost 100 people attending.

We felt that disseminating information on what we had learned from the conference was a critical success factor, so we produced both a report and a film which included top-line commentary from several of the event speakers about their work and what they hope it will achieve for people with rare and less common cancers.⁹ The report covered the same territory but in more detail.¹⁰

Patient survey report

During the summer of 2019, we produced a report on the experiences of people with rare and less common cancers based on the nearly 700 responses we generated in our conversations with patients in the run-up to publication of the NHS Long Term Plan.

We marked its publication¹¹ with a special drop-in event at Portcullis House in London on 10 July 2019. The report, 'Getting a better deal for rare and less common cancers: One year on from the NHS Long Term Plan',¹² highlights the difficulties and delays often faced by patients with rare and less common cancers when trying to obtain a diagnosis, information which we will use to inform our activities across the board.



Annual Stakeholder Briefing

Our Annual Stakeholder Briefing was held in London on 16 October 2019.¹³ The keynote speaker was David Fitzgerald, Cancer Programme Director at NHS England, who presented an update on the NHS Long Term Plan, explaining the shift in focus to early diagnosis, which was so strongly influenced by **Cancer52** input. He outlined the initial priorities to bring about the changes, which include the development of a service specification for early diagnosis, a clinical review of standards and delivery of cancer services.

Other influential speakers from NICE included Heidi Livingstone, Public Involvement Adviser, and Lizzie Thomas, Senior Public Involvement Adviser. Heidi talked about the way in which NICE involves patients in their work, a theme in which **Cancer52** has a specific interest. Lizzie explained how life evidence and qualitative evidence both play a crucial role in NICE methods and processes. We were also able to make a presentation to outline our achievements for the year.

Our vision does not waver: we will champion the needs of those with rare and less common cancers

Our future vision does not waver: we will do everything in our power to champion the needs of those with rare and less common cancers by all the means at our disposal so that we can improve early diagnosis, treatment options and outcomes.

We will research, lobby, network, promote, discuss, campaign and get involved at the highest level in the cancer community to give a voice to the concerns and requirements of our member charities. Our approach will remain resourceful and flexible in order to deal with the unique difficulties that the year ahead will bring as a result of the Covid-19 pandemic.

Supporting the NHS Long Term Plan will clearly be at the heart of our progress. We have already demonstrated our influence within the LTP early diagnosis targets. We will continue to build on those achievements.

The year 2020–2021 will be dominated by Covid-19 in every health sector and in the field of cancer in particular. We will look to support our member charities better than ever before and build on our past achievements in order to become an even stronger voice in the cancer arena.

Our support: sources of funding

The value of our support

In 2019–2020, we received funding from a variety of sources: donations from members; individual donations; and support from pharmaceutical companies.

As a significant number of **Cancer52** members have an income of less than £250k, the Board has agreed a funding model that is not reliant on funding from our members, but instead seeks funding from external partners, trusts and foundations.

We are hugely grateful to every donor for their financial support which enables us to operate in furtherance of our objectives. While the financial contribution of our charity members does not equal that of the pharmaceutical companies, it represents a very significant contribution in terms of number and variety of organisations who support **Cancer52**. Many of these contribute a significant percentage of their own income, and we highly value their contributions.

We are hugely grateful to every donor for their financial support.



'We note the great progress made by Cancer52 and the plans for the year ahead and we are delighted to continue our membership.'

Richard Davidson, Chief Executive, Sarcoma UK

Support from industry

We seek financial support from industry and in 2019–2020 we received support from Bristol-Myers Squibb, Clinigen, Janssen, and Pfizer.

Cancer52 has a clear policy on working with the pharmaceutical industry and abides by industry guidelines.¹⁴ 71% of our funding comes from pharmaceutical companies. This comprises support for specific projects as well as unrestricted support.

The contribution we received from Pfizer in this year was designated to build an awareness campaign for rare and less common cancers. This project launch was delayed because of the Covid-19 outbreak but development work on the campaign has continued and we hope to launch by spring 2021.

We believe all our industry partners recognise the value of dealing with one body that brings together one voice for rare and less common cancers. It is this single voice that represents the combined knowledge and expertise of the member charities that can be heard at the highest level of cancer policy and influence.

Working with us also offers a unique opportunity to engage with the expertise and knowledge gained through the relationships we enjoy with our member organisations, all of which are very close to their patients.



'We're very proud to be part of Cancer52.'

Nikie Jervis, Patient Information and Support Nurse Specialist, Education Lead, NET Patient Foundation

Voluntary member donations

The vast majority of our financial supporters are our member charities, who we ask for a donation to our work that is allied to the income of the charity. We aim to offer free membership to smaller charities with financial challenges, although, in many cases, they decide they would like to make a contribution because they so value the work we do together.

61 member charities donated to our work in 2019–2020.

In addition, support comes not only in financial form, but also in the valuable time, expertise and energy which are so generously given by our members, and for which we are equally appreciative.

Trusts and individual donations

Donations are welcome from any individuals or organisations who recognise the value of our contribution to supporting people with rare and less common cancers.

From October 2019 to March 2020, we invested in a programme to develop fundraising applications. We were preparing to submit the first round of applications when the Covid-19 pandemic hit. Since this was clearly not the right time to make such applications, the project was put on hold and the situation will be reviewed in autumn 2020.

61
of our member charities supported our work financially as well as with great expertise and collaborative commitment



Cancer52 engages with NICE on a broad level, usually involving topics concerning patient involvement or wider changes, but does not engage in any individual drug applications or appraisals.

The acoustics: structure and constitution

Structure and governance

Cancer52 is incorporated as a charitable company limited by guarantee and is a registered charity in England and Wales. It is governed by its Memorandum and Articles of Association, and the work, management, finances and strategy of the charity are overseen by a Board of Trustees, who are also the company directors. The Trustees who held office during the financial year and at the date of the report are set out on page 41.

Under the Articles of Association, a minimum of three trustees and a maximum of twelve trustees can be in office. At Annual General Meetings, one-third of the existing directors must retire by rotation based on the longest serving directors retiring first. Retiring directors may be re-appointed at Annual General Meetings by the vote of existing directors. New directors may only be appointed at Annual General Meetings where the notice and approval requirements set out in the Articles of Association have been satisfied.

The Board has agreed that the usual term of tenure for trustees should be a maximum of two terms of three years each (six years in total), with review and approval by the Board at the end of each term of tenure. In exceptional circumstances, and in order not to lose important or valuable skills, experience and expertise, trustees may serve for a third term of tenure, subject to the approval of the Board. Trustees do not receive remuneration for their duties.



'Membership of Cancer52 has helped us to gain a good knowledge of the important debates around cancer issues; access to key players; a raised profile; and advice from other member organisations with greater experience.'


John Symons, Director, Cancer of Unknown Primary (CUP) Foundation

Purpose

The charity's purposes are set out in its Memorandum and Articles of Association as follows:

To promote and protect the health of sufferers of rare and less common cancers for the public benefit by:

- 1 advancing and promoting the understanding, awareness, research and learning about rare and less common cancers;
- 2 acting as a collective voice and advocating for the needs of individuals affected by a rare or less common cancer in order to improve the outcomes of diagnosis, treatment and long-term support; and
- 3 supporting, representing and empowering not-for-profit organisations working in the field of rare and less common cancer.



Honorary President of Cancer52, Baroness Morgan of Drefelin



Board and management operations and structure

Board of Trustees

The Board of Trustees meets at least four times a year to review the organisation's work, finances and services, and to agree the strategic goals for the charity. The chief executive attends all meetings. The Board is also establishing a process to review its own operation, effectiveness and governance.

The chair and another trustee with financial expertise also meet separately with the chief executive and the charity's accountant on a quarterly basis to monitor and scrutinise the charity's financial strategy and operations, and make any necessary recommendations to the full Board of Trustees.

Recruitment and appointment of new trustees

An annual review of the recruitment needs of the Board of Trustees is carried out under the leadership of the chair, including an audit of the current knowledge, experience, skills and abilities, and how they will be affected by any trustee departures in the future. Any trustee vacancies are advertised nationally, and via relevant professional and organisational networks, including the charity's own member organisations, depending upon the expertise and specialisms required. Applicants are shortlisted against the criteria in the person specification for the role of trustee, including any specific qualities highlighted during the above audit. Shortlisted applicants are invited for interview by at least two trustees, one of whom will be the chair. Shortlisted applicants are only appointed where they have the necessary skills and qualities to contribute effectively to the charity's governance and development.

Public benefit

Our work delivers public benefit by providing information and support to people diagnosed with, treated for or living with a rare or less common cancer through the services, interactions and collaboration that we facilitate between our members. The influencing work we carry out to drive change and enhancements in the cancer system provides public benefit through improving outcomes for people affected by a rare or less common cancer.

As part of our business planning processes, we review our aims and objectives each year, which includes looking at what we have achieved in previous years, and how our activities have benefited those groups of people we were set up to help. We have referred to the Charity Commission's general guidance on public benefit when reviewing our aims and objectives, and in planning our work for the future.

All new trustees receive thorough induction and training, which includes detailed information about the association, including its memorandum and articles, accounts, financial reports and minutes of previous meetings of the trustees.

Day-to-day operation of the charity, and strategy implementation, is delegated to the chief executive.

Related parties

The only related parties are considered to be the trustees and those connected with the trustees, including their close families, business and other charity interests. There have been no transactions with related parties, other than the reimbursement of reasonable travel expenses for the purposes of attendance at Board meetings and other relevant organisational activities.



'The Debbie Fund Advisory Board have agreed that Debbie Fund should continue to support the valuable work of Cancer52 through membership. We are most grateful for all the work Cancer52 does to provide a voice for the less common cancers, such as cervical cancers.'

Katy Moyle, Chair, Debbie Fund Advisory Board

Risk assessment and management

The Board of Trustees and the chief executive maintain a risk register and assess risks on an annual basis. The trustees are satisfied that the major risks to the organisation have been accurately identified and that appropriate systems and procedures for managing those risks are in place. The main areas of identified risk are in relation to:

- lack of investment in the organisation's capacity and staffing
- income generation, namely, failing to secure existing funding streams, as well as failing to develop a more diverse range of income streams
- external reputation, namely that a policy position or external statement damages the organisation's profile with key stakeholders, including member organisations, NHS policymakers or funders/supporters

To address these risks, effective management and controls have been put in place by the trustees, including:

- strong and regular review of income generation activity by the Board of Trustees
- the development and approval of a new strategic plan covering the period from 2018 to 2020 focusing on growth and sustainability for **Cancer52** as an organisation, with an allied ambition to be at the forefront of developing a new rare and less common cancer strategy within the NHS
- running a Policy and Public Affairs Steering Group (reporting into the chief executive and Board of Trustees), which brings together key policy/public affairs staff from a number of cancer support/campaigning organisations, so that they can develop and advise on **Cancer52's** external policy positions
- appropriate insurance cover and associated measures

Money talks: financial review

Financial statement

As shown in the statement of financial activities on the following pages, in the year 2019–2020:

- reserves brought forward from 2018–2019 were £68,402
- income for the financial year was £109,038
- expenditure for the current financial year was £110,377, resulting in a small, anticipated deficit of £1,339
- reserves of £67,063 were available at the end of the 2019–2020 financial year

Reserves policy

The Board of Trustees' strategy on reserves is for the organisation to maintain sufficient funds to cover the operational running costs in the event of a major setback. This means that we aim to hold approximately six months' annual expenditure in reserve.

At the end of the 2019–2020 financial year, our reserves stood at £67,063 which adequately covers the six months required.

The Company has taken advantage of the small companies exemption in preparing this report. The trustees declare that they have approved the trustees' report (including directors' report) above.

Signed on behalf of the charity's trustees/directors

Signature _____

Jonathan Pearce

Trustee / Director

Date _____

Signature _____

Nic Puntis

Trustee / Director

Date _____

Independent examiners' report to the trustees of **Cancer52**

Respective responsibilities of the trustees and the examiner

The charity's trustees are responsible for the preparation of the accounts. The charity's trustees consider that an audit is not required for this year under section 144 of the Charities Act 2011 ('the Charities Act') and that an independent examination is needed.

Recruitment and appointment of new trustees

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 March 2020.

As the charity's trustees of the Company (who are also the directors of the Company for the purposes of company law), you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited for this year under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination, I have followed the Directions given by the Charity Commission (under section 145(5)(b) of the 2011 Act).

It is my responsibility to:

- examine the accounts under section 145 of the Charities Act
- follow the procedures laid down in the general directions given by the Charity Commission (under section 145(5)(b) of the Charities Act and
- state whether particular matters have come to my attention

Basis of independent examiner's statement

My examination was carried out in accordance with general directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts and seeking explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently no opinion is given as to whether the accounts present a 'true and fair' view and the report is limited to those matters set out in the statement below.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention which give me cause to believe that:

- accounting records were not kept in accordance with section 386 of the Companies Act 2006; or
- the accounts do not accord with such records; or
- the accounts do not comply with relevant accounting requirements under section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
- the accounts have not been prepared in accordance with the Charities SORP (FRS102).
- I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signature _____

Jason Dennis of J & H Accounting Services

Date _____

Relevant professional qualification(s) or body
Association of Accounting Technicians AAT
31 Clover Way, Paddock Wood, Tonbridge, Kent, TN12 6BQ

Section A

Statement of financial activities

(including summary income and expenditure account)

Recommended categories by activity	Guidance Note	Unrestricted funds	Restricted income funds	Endowment funds	Total funds	Prior year funds
		£ F01	£ F02	£ F03	£ F04	£ F05
Income (Note 3)						
Income and endowments from:						
Donations and legacies	S01	109,038	-	-	109,038	98,491
Total	S07	109,038	-	-	109,038	98,491
Expenditure (Notes 4)						
Expenditure on:						
Raising funds	S08	4,470	-	-	4,470	-
Charitable activities	S09	104,107	-	-	104,107	106,188
Other	S11	1,800	-	-	1,800	1,800
Total	S12	110,377	-	-	110,377	107,988
Net income/(expenditure) before tax for the reporting period	S13	(1,339)	-	-	(1,339)	(9,497)
Tax payable	S14	-	-	-	-	-
Net income/(expenditure) after tax before investment gains/(losses)	S15	(1,339)	-	-	(1,339)	(9,497)
Net gains/(losses) on investments	S16	-	-	-	-	-
Net income/(expenditure) Extraordinary items	S17	(1,339)	-	-	(1,339)	(9,497)
Transfers between funds	S18	-	-	-	-	-
Other recognised gains/(losses):	S19	-	-	-	-	-
Gains and losses on revaluation of fixed assets for the charity's own use	S20	-	-	-	-	-
Other gains/(losses)	S21	-	-	-	-	-
Net movement in funds	S22	(1,339)	-	-	(1,339)	(9,497)
Reconciliation of funds:						
Total funds brought forward	S23	68,402	-	-	68,402	77,899
Total funds carried forward	S24	67,063	-	-	67,063	68,402

Section B

Balance sheet

Current assets						
Cash at bank and in hand (Note 24)	B09	68,863	-	-	68,863	70,202
Total current assets	B10	68,863	-	-	68,863	70,202
Creditors: amounts falling due within one year (Note 6)	B11	1,800	-	-	1,800	1,800
Net current assets/(liabilities)	B12	67,063	-	-	67,063	68,402
Total assets less current liabilities	B13	67,063	-	-	67,063	68,402
Total net assets or liabilities	B16	67,063	-	-	67,063	68,402
Funds of the Charity						
Endowment funds (Note 27)	B17	-	-	-	-	-
Restricted income funds (Note 27)	B18	-	-	-	-	-
Unrestricted funds	B19	67,063	-	-	67,063	68,402
Revaluation reserve	B20	-	-	-	-	-
Fair value reserve	B21	-	-	-	-	-
Total funds	B22	67,063	-	-	67,063	68,402

The company was entitled to exemption from audit under s477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to small companies subject to the small companies regime and in accordance with FRS102 SORP.

Signed by one or two trustees/directors on behalf of all the trustees/directors

Print Name	Date of approval dd/mm/yyyy
Jonathan Pearce	
Nic Puntis	

Signature of director authenticating accounts being sent to Companies House

Print name	Date dd/mm/yyyy
Jonathan Pearce	

Section C

Notes to the accounts

NOTE 1: Basis of preparation

This section should be completed by all charities.

1.1 Basis of accounting

These accounts have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant note(s) to these accounts.

The accounts have been prepared in accordance with:

- and with* the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 16 July 2014
- and with* the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102)
- and with the Charities Act 2011.

The charity constitutes a public benefit entity as defined by FRS 102.*

* -Tick as appropriate

1.2 Going concern

If there are material uncertainties related to events or conditions that cast significant doubt on the charity's ability to continue as a going concern, please provide the following details or state "Not applicable", if appropriate:

An explanation as to those factors that support the conclusion that the charity is a going concern;

Not applicable

Disclosure of any uncertainties that make the going concern assumption doubtful;

Not applicable

Where accounts are not prepared on a going concern basis, please disclose this fact together with the basis on which the trustees prepared the accounts and the reason why the charity is not regarded as a going concern.

Not applicable

1.3 Change of accounting policy

The accounts present a true and fair view and no changes have been made to the accounting policies adopted in note { }.

Yes* No* * -Tick as appropriate

Please disclose:

(i) the nature of the change in accounting policy;	Not applicable
(ii) the reasons why applying the new accounting policy provides more reliable and more relevant information; and	Not applicable
(iii) the amount of the adjustment for each line affected in the current period, each prior period presented and the aggregate amount of the adjustment relating to periods before those presented, 3.44 FRS102 SORP.	Not applicable

1.4 Changes to accounting estimates

No changes to accounting estimates have occurred in the reporting period (3.46 FRS102 SORP).

Yes* No* * -Tick as appropriate

Please disclose:

(i) the nature of any changes;	Not applicable
(ii) the effect of the change on income and expense or assets and liabilities for the current period; and	Not applicable
(iii) where practicable, the effect of the change in one or more future periods.	Not applicable

1.5 Material prior year errors

No material prior year error have been identified in the reporting period (3.47 FRS102 SORP).

Yes* No* * -Tick as appropriate

Please disclose:

(i) the nature of the prior period error;	Not applicable
(ii) for each prior period presented in the accounts, the amount of the correction for each account line item affected; and	Not applicable
(iii) the amount of the correction at the beginning of the earliest prior period presented in the accounts.	Not applicable

NOTE 2: Accounting policies

2.1 INCOME

Recognition of income	These are included in the Statement of Financial Activities (SoFA) when: <ul style="list-style-type: none"> the charity becomes entitled to the resources; it is more likely than not that the trustees will receive the resources; the monetary value can be measured with sufficient reliability. 	Yes* <input checked="" type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input type="checkbox"/>
Offsetting	There has been no offsetting of assets and liabilities, or income and expenses, unless required or permitted by the FRS 102 SORP or FRS 102.	Yes* <input checked="" type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input type="checkbox"/>
Grants and donations	Grants and donations are only included in the SoFA when the general income recognition criteria are met (5.10 to 5.12 FRS102 SORP). In the case of performance related grants, income must only be recognised to the extent that the charity has provided the specified goods or services as entitlement to the grant only occurs when the performance related conditions are met (5.16 FRS 102 SORP).	Yes* <input checked="" type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input type="checkbox"/>
Legacies	Legacies are included in the SOFA when receipt is probable, that is, when there has been grant of probate, the executors have established that there are sufficient assets in the estate and any conditions attached to the legacy are either within the control of the charity or have been met.	Yes* <input type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input checked="" type="checkbox"/>
Government grants	The charity has received government grants in the reporting period	Yes* <input type="checkbox"/>	No* <input checked="" type="checkbox"/>	N/a* <input type="checkbox"/>
Tax reclaims on donations and gifts	Gift Aid receivable is included in income when there is a valid declaration from the donor. Any Gift Aid amount recovered on a donation is considered to be part of that gift and is treated as an addition to the same fund as the initial donation unless the donor or the terms of the appeal have specified otherwise.	Yes* <input checked="" type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input type="checkbox"/>
Contractual income and performance related grants	This is only included in the SoFA once the charity has provided the related goods or services or met the performance related conditions.	Yes* <input type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input checked="" type="checkbox"/>
Donated goods	Donated goods are measured at fair value (the amount for which the asset could be exchanged) unless impractical to do so. The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt and they are recognised on receipt. In the reporting period in which the stocks are distributed, they are recognised as an expense at the carrying amount of the stocks at distribution. Donated goods for resale are measured at fair value on initial recognition, which is the expected proceeds from sale less the expected costs of sale, and recognised in 'Income from other trading activities' with the corresponding stock recognised in the balance sheet. On its sale the value of stock is charged against 'Income from other trading activities' and the proceeds from sale are also recognised as 'Income from other trading activities'. Goods donated for on-going use by the charity are recognised as tangible fixed assets and included in the SoFA as incoming resources when receivable.	Yes* <input type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input checked="" type="checkbox"/>
	Gifts in kind for use by the charity are included in the SoFA as income from donations when receivable.	Yes* <input type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input checked="" type="checkbox"/>
Donated services and facilities	Donated services and facilities are included in the SOFA when received at the value of the gift to the charity provided the value of the gift can be measured reliably. Donated services and facilities that are consumed immediately are recognised as income with an equivalent amount recognised as an expense under the appropriate heading in the SOFA.	Yes* <input type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input checked="" type="checkbox"/>
Support costs	The charity has incurred expenditure on support costs.	Yes* <input type="checkbox"/>	No* <input checked="" type="checkbox"/>	N/a* <input type="checkbox"/>
Volunteer help	The value of any voluntary help received is not included in the accounts but is described in the trustees' annual report.	Yes* <input type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input checked="" type="checkbox"/>

Income from interest, royalties and dividends	This is included in the accounts when receipt is probable and the amount receivable can be measured reliably.	Yes* <input checked="" type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input type="checkbox"/>
Income from membership subscriptions	Membership subscriptions received in the nature of a gift are recognised in Donations and Legacies. Membership subscriptions which gives a member the right to buy services or other benefits are recognised as income earned from the provision of goods and services as income from charitable activities.	Yes* <input checked="" type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input type="checkbox"/>
Settlement of insurance claims	Insurance claims are only included in the SoFA when the general income recognition criteria are met (5.10 to 5.12 FRS102 SORP) and are included as an item of other income in the SoFA.	Yes* <input type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input checked="" type="checkbox"/>
Investment gains and losses	This includes any realised or unrealised gains or losses on the sale of investments and any gain or loss resulting from revaluing investments to market value at the end of the year.	Yes* <input type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input checked="" type="checkbox"/>

2.2 EXPENDITURE AND LIABILITIES

Liability recognition	Liabilities are recognised where it is more likely than not that there is a legal or constructive obligation committing the charity to pay out resources and the amount of the obligation can be measured with reasonable certainty.	Yes* <input checked="" type="checkbox"/>	No* <input checked="" type="checkbox"/>	N/a* <input checked="" type="checkbox"/>
Governance and support costs	Support costs have been allocated between governance costs and other support. Governance costs comprise all costs involving public accountability of the charity and its compliance with regulation and good practice. Support costs include central functions and have been allocated to activity cost categories on a basis consistent with the use of resources, eg allocating property costs by floor areas, or per capita, staff costs by the time spent and other costs by their usage.	Yes* <input type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input checked="" type="checkbox"/>
Grants with performance conditions	Where the charity gives a grant with conditions for its payment being a specific level of service or output to be provided, such grants are only recognised in the SoFA once the recipient of the grant has provided the specified service or output.	Yes* <input type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input checked="" type="checkbox"/>
Grants payable without performance conditions	Where there are no conditions attaching to the grant that enables the donor charity to realistically avoid the commitment, a liability for the full funding obligation must be recognised.	Yes* <input type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input checked="" type="checkbox"/>
Redundancy cost	The charity made no redundancy payments during the reporting period.	Yes* <input type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input checked="" type="checkbox"/>
Deferred income	No material item of deferred income has been included in the accounts.	Yes* <input type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input checked="" type="checkbox"/>
Creditors	The charity has creditors which are measured at settlement amounts less any trade discounts	Yes* <input type="checkbox"/>	No* <input checked="" type="checkbox"/>	N/a* <input type="checkbox"/>
Provisions for liabilities	A liability is measured on recognition at its historical cost and then subsequently measured at the best estimate of the amount required to settle the obligation at the reporting date	Yes* <input type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input checked="" type="checkbox"/>
Basic financial instruments	The charity accounts for basic financial instruments on initial recognition as per paragraph 10.7 FRS102 SORP. Subsequent measurement is as per paragraphs 11.17 to 11.19, FRS102 SORP.	Yes* <input type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input checked="" type="checkbox"/>
2.3 ASSETS				
Tangible fixed assets for use by charity	These are capitalised if they can be used for more than one year, and cost at least £2,500 They are valued at cost. The depreciation rates and methods used are disclosed in note 14.	£2,500		
		Yes* <input type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input checked="" type="checkbox"/>
Intangible fixed assets	The charity has intangible fixed assets, that is, non-monetary assets that do not have physical substance but are identifiable and are controlled by the charity through custody or legal rights. The amortisation rates and methods used are disclosed in note 15. They are valued at cost.	Yes* <input type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input checked="" type="checkbox"/>
Heritage assets	The charity has heritage assets, that is, non-monetary assets with historic, artistic, scientific, technological, geophysical or environmental qualities that are held and maintained principally for their contribution to knowledge and culture. The depreciation rates and methods used as disclosed in note 16. They are valued at cost.	Yes* <input type="checkbox"/>	No* <input type="checkbox"/>	N/a* <input checked="" type="checkbox"/>

Investments

Fixed asset investments in quoted shares, traded bonds and similar investments are valued at initially at cost and subsequently at fair value (their market value) at the year end. The same treatment is applied to unlisted investments unless fair value cannot be measured reliably in which case it is measured at cost less impairment.

Yes*	No*	N/a*
		✓

Investments held for resale or pending their sale and cash and cash equivalents with a maturity date of less than 1 year are treated as current asset investments

Yes*	No*	N/a*
		✓

Stocks and work in progress

Stocks held for sale as part of non-charitable trade are measured at the lower or cost or net realisable value.

Yes*	No*	N/a*
		✓

Goods or services provided as part of a charitable activity are measured at net realisable value based on the service potential provided by items of stock.

Yes*	No*	N/a*
		✓

Work in progress is valued at cost less any foreseeable loss that is likely to occur on the contract.

Yes*	No*	N/a*
		✓

Debtors

Debtors (including trade debtors and loans receivable) are measured on initial recognition at settlement amount after any trade discounts or amount advanced by the charity. Subsequently, they are measured at the cash or other consideration expected to be received.

Yes*	No*	N/a*
		✓

Current asset investments

The charity has investments which it holds for resale or pending their sale and cash and cash equivalents with a maturity date less than one year. These include cash on deposit and cash equivalents with a maturity of less than one year held for investment purposes rather than to meet short-term cash commitments as they fall due.

Yes*	No*	N/a*
		✓

They are valued at fair value except where they qualify as basic financial instruments.

Yes*	No*	N/a*
		✓

POLICIES ADOPTED ADDITIONAL TO OR DIFFERENT FROM THOSE ABOVE

NOTE 4: Expenditure

Analysis	This year			Last year			Total funds
	Unrestricted funds	Restricted income funds	Endowment funds	Unrestricted funds	Restricted income funds	Endowment funds	
Expenditure on raising funds							
Fundraising consultants	4,470	-	-	4,470	-	-	-
Total expenditure on raising funds	4,470	-	-	4,470	-	-	-
Expenditure on charitable activities:							
All Member Meetings, Steering Group Meetings, Room Hire, Venue Costs	1,772	-	-	1,772	3,778	-	3,778
Britain Against Cancer Conference expenses	-	-	-	-	430	-	430
Secretarial expenses	21,708	-	-	21,708	15,807	-	15,807
Subscriptions	241	-	-	241	2,426	-	2,426
Patient Experience Report	-	-	-	-	510	-	510
Patient Report	9,327	-	-	9,327	-	-	-
Patient Support Project	1,915	-	-	1,915	-	-	-
Printing, postage and stationery	-	-	-	-	1,430	-	1,430
Filming at Conferences	2,315	-	-	2,315	4,573	-	4,573
Visual Image Consultants	-	-	-	-	250	-	250
Photography of Meetings and Briefings for reports	1,575	-	-	1,575	-	-	-
IT and Computer running expenses	47	-	-	47	502	-	502
Policy consultants - Policy Support	6,400	-	-	6,400	17,041	-	17,041
Policy Roundtable	2,500	-	-	2,500	5,140	-	5,140
Policy Report	4,000	-	-	4,000	-	-	-
Interim Policy Consultants	-	-	-	-	1,757	-	1,757
Insurance	487	-	-	487	483	-	483
Management and Administration	38,480	-	-	38,480	38,512	-	38,512
Communications	9,620	-	-	9,620	9,628	-	9,628
Bank and credit fees	3,063	-	-	3,063	3,921	-	3,921
Trustees/Directors Travel	401	-	-	401	-	-	-
Patients Travel	256	-	-	256	-	-	-
	-	-	-	-	-	-	-
Total expenditure on charitable activities	104,107	-	-	104,107	106,188	-	106,188
Other							
Independent Examiner	1,800	-	-	1,800	-	-	-
Total other expenditure	1,800	-	-	1,800	-	-	-
TOTAL EXPENDITURE	110,377	-	-	110,377	106,188	-	106,188

NOTE 3: Income

Analysis of income	Unrestricted funds	Restricted income funds	Endowment funds	Total funds	Prior year
Donations and gifts	78,104	-	-	78,104	84,641
Gift Aid	314	-	-	314	-
Membership subscriptions and sponsorships which are in substance donations	30,620	-	-	30,620	13,850
Total	109,038	-	-	109,038	98,491
TOTAL INCOME	109,038	-	-	109,038	98,491

NOTE 5: Details of certain types of expenditure

Note 5.1 Fees for examination of the accounts

Please provide details of the amount paid for any statutory external scrutiny of accounts and other services provided by your independent examiner. If nothing was paid please enter '0' in the appropriate box(es).

Independent examiner's fees

This year	Last year
£	£
1,800	1,800

NOTE 6: Creditors and accruals

Please complete this note if the charity has any creditors or accruals.

6.1 Analysis of creditors

	Amounts falling due within one year		Amounts falling due after more than one year	
	This year £	Last year £	This year £	Last year £
Accruals and deferred income	1,800	1,800	-	-
Other creditors	-	-	-	-
Total	1,800	1,800	-	-

NOTE 7: Cash at bank and in hand

Cash at bank and on hand
Total

This year £	Last year £
68,863	70,202
68,863	70,202

NOTE 8: Fair value of assets and liabilities

8.1 Please provide details of the charity's exposure to credit risk (the risk of incurring a loss due to a debtor not paying what is owed), liquidity risk (the risk of not being able to meet short term financial demands) and market risk (the risk that the value of an investment will fall due to changes in the market) arising from financial instruments to which the charity is exposed at the end of the reporting period and explain how the charity manages those risks.

This year	Last year
Credit risk is low due to income being in the form of donations. Cash is the only investment so market risk is low on investment values falling. Liquidity risk is low as costs are managed in relation to income received.	Credit risk is low due to income being in the form of donations. Cash is the only investment so market risk is low on investment values falling. Liquidity risk is low as costs are managed in relation to income received.

8.2 Please give details of the amount of change in the fair value of basic financial instruments (debtors, creditors, investments (see section 11, FRS 102 SORP)) measured at fair value through the SoFA that is attributable to changes in credit risk.

This year	Last year
Not applicable	Not applicable

NOTE 9: Charity funds

9.1 Details of material funds held and movements during the CURRENT reporting period

Please give details of the movements of material individual funds in the reporting period together with a balancing figure for 'Other funds' (which should include revaluation reserve and fair value reserve, if applicable). The 'Total funds' figure below should reconcile to 'Total funds' in the balance sheet.

* Key: PE - permanent endowment funds; EE - expendable endowment funds; R - restricted income funds, including special trusts, of the charity; and U - unrestricted funds

Fund names	Type PE, EE R or UR *	Purpose and Restrictions	Fund balances brought forward £	Income £	Expenditure £	Transfers £	Gains and losses £	Fund balances carried forward £
General Fund	UR	General all purpose no restrictions	68,402	109,038	(110,377)	-	-	67,063
Total Funds as per balance sheet			68,402	109,038	(110,377)	-	-	67,063

Fund balances carried forward include assets and liabilities denominated in a foreign currency

Yes*	No*
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>

If yes, please state the basis on which the assets and/or liabilities have been translated into sterling (or the currency in which the accounts are drawn up).

9.2 Details of material funds held and movements during the PREVIOUS reporting period

Please give details of the movements of material individual funds in the reporting period together with a balancing figure for 'Other funds' (which should include revaluation reserve and fair value reserve, if applicable). The 'Total funds' figure below should reconcile to 'Total funds' in the balance sheet.

* Key: PE - permanent endowment funds; EE - expendable endowment funds; R - restricted income funds, including special trusts, of the charity; and U - unrestricted funds

Fund names	Type PE, EE R or UR *	Purpose and Restrictions	Fund balances brought forward £	Income £	Expenditure £	Transfers £	Gains and losses £	Fund balances carried forward £
General Fund	UR	General all purpose no restrictions	77,899	98,491	(107,988)	-	-	68,402
Total Funds as per balance sheet			77,899	98,491	(107,988)	-	-	68,402

Fund balances carried forward include assets and liabilities denominated in a foreign currency

Yes*	No*
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>

NOTE 10: Transactions with trustees and related parties

If the charity has any transactions with related parties (other than the trustee expenses explained in guidance notes) details of such transactions should be provided in this note. If there are no transactions to report, please enter "True" in the box or "False" if there are transactions to report.

10.1 Trustee remuneration and benefits

This year

None of the trustees have been paid any remuneration or received any other benefits from an employment with their charity or a related entity (True or False)

TRUE

10.2 Trustees' expenses

If the charity has paid trustees expenses for fulfilling their duties, details of such transactions should be provided in this note. If there are no transactions to report, please enter "True" in the box below. If there are transactions to report, please enter "False".

No trustee expenses have been incurred (True or False)

FALSE

Type of expenses reimbursed	This year	Last year
	£	£
Travel	401	-
TOTAL	401	-

Please provide the number of trustees reimbursed for expenses or who had expenses paid by the charity

1	0
---	---

10.3 Transaction(s) with related parties

Please give details of any transaction undertaken by (or on behalf of) the charity in which a related party has a material interest, including where funds have been held as agent for related parties. If there are no such transactions, please enter 'true' in the box provided.

This year

There have been no related party transactions in the reporting period (True or False)

TRUE

Last year

There have been no related party transactions in the reporting period (True or False)

TRUE



CHARITY COMMISSION
FOR ENGLAND AND WALES

Independent examiner's report
on the accounts

Section A

Independent Examiner's Report

Report to the
trustees/directors/
members of

Cancer52

On accounts for the year
ended

31 March 2020

Charity no.:

1174569

Company no.:

07994413

Set out on pages

39 – 40

Responsibilities and
basis of report

I report to the charity trustees on my examination of the accounts of the Company for the year ended **31 / 03 / 2020**.

As the charity's trustees of the Company (who are also the directors of the company for the purposes of company law), you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ("the 2006 Act").

Having satisfied myself that the accounts of the Company are not required to be audited for this year under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ("the 2011 Act"). In carrying out my examination, I have followed the Directions given by the Charity Commission (under section 145(5)(b) of the 2011 Act).

Independent
examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention which gives me cause to believe that:

- accounting records were not kept in accordance with section 386 of the Companies Act 2006; or
- the accounts do not accord with such records; or
- the accounts do not comply with relevant accounting requirements under section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
- the accounts have not been prepared in accordance with the Charities SORP (FRS102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed: Date: 28th July 2020

Name: Jason Dennis of J & H Accounting Services Limited

Relevant professional qualification(s) or body (if any): Association of Accounting Technicians AAT

Address: 31 Clover Way, Paddock Wood, Tonbridge, Kent, TN12 6BQ

Section B Disclosure

Only complete if the examiner needs to highlight material matters of concern (see CC32, Independent examination of charity accounts: directions and guidance for examiners).

Give here brief details of any items that the examiner wishes to disclose.

Administrative details

TRUSTEES

Jonathan Pearce,
Sasha Daly *
Lindsey Bennister
Helen Morement
Rebecca Porta
Nic Puntis
Rebecca Rennison
John Symons
Christopher Walden

Chair
Vice chair

EXECUTIVE OFFICERS

Baroness Morgan of Drefelin President
Jane Lyons Chief executive
Jonathan Pearce Company secretary

BANKERS

Co-operative Bank

* Resigned March 2020

References

¹ PHE/NCRAS May 2019 or source cancerresearchuk.org/cancer-info/cancerstats/

² [ii] Cancer52 membership research, conducted April 2019

³ <https://www.rarecancerseurope.org/About-Rare-Cancers>

⁴ longtermpplan.nhs.uk/areas-of-work/cancer/

⁵ <https://www.england.nhs.uk/cancer/strategy/our-governance/>

⁶ england.nhs.uk/2019/06/fast-track-game-changing-cancer-drugs/

⁷ <https://www.rarerevolutionmagazine.com/>

⁸ cancer52.org.uk/single-post/2019/01/07/Cancer52-welcomes-NHS-Long-Term-Plan

⁹ <https://www.cancer52.org.uk/single-post/2019/07/17/Summary-of-Cancer52-PHE-Event-Development-in-Data-for-Rare-and-Less-Common-Cancers>

¹⁰ <https://vimeopro.com/warnervision/cancer52-may-2019>

¹¹ <https://www.ncpes.co.uk/2019-national-level-results/>

¹² https://53d93de1-1a6c-449b-9a6d-4761eb1a07f5.filesusr.com/ugd/e22361_3419733e6074483aa7db8ddc841_bd469.pdf

¹³ <https://www.cancer52.org.uk/single-post/2019/05/14/16-october-2017-all-stakeholder-meeting>

¹⁴ https://53d93de1-1a6c-449b-9a6d-4761eb1a07f5.filesusr.com/ugd/e22361_f394024ec51f4281b304cf1c69ddacbd.pdf

List of charity members 2019/20

ACLT (African Caribbean Leukaemia Trust)
www.aclt.org

Act for Cancer
www.actforcancer.org.uk

Action Against Heartburn
www.actionagainstheartburn.org.uk

Action Bladder Cancer UK
www.actionbladdercanceruk.org

Action on Womb Cancer
www.actiononwombcancer.org.uk

ALK Positive Lung Cancer
www.alkpositive.org.uk

AMMF – The Cholangiocarcinoma Charity
www.ammf.org.uk

Association for Multiple Endocrine Neoplasia Disorders (AMEND)
www.amend.org.uk

Baggy Trousers UK
www.baggytrousersuk.org

Balls to Cancer
www.ballstocancer.co.uk

Barrett's Oesophagus UK
www.barrettscampaign.org.uk

Blood Cancer UK (formerly Bloodwise)
www.bloodcancer.org.uk

Bone Cancer Research Trust
www.bcrct.org.uk

Brain Tumour Research
www.braintumourresearch.org

Brain Tumour Research Campaign (Wayahead)
www.btrc-charity.org

Brainstrust
www.brainstrust.org.uk

British Lymphology Society (BLS)
www.thebls.com

British Thyroid Foundation (BTF-thyroid)
www.btf-thyroid.org

Butterfly Thyroid Cancer Trust (BTCT)
www.butterfly.org.uk

Cancer Laryngectomy Trust
www.cancerlt.org

Cancer of Unknown Primary (CUP) Foundation – Jo's friends
www.cupfoundjo.org

Childhood Eye Cancer Trust (CHECT)
www.chect.org.uk

Children's Cancer and Leukaemia Group (CCLG)
www.cclg.org.uk

Chordoma UK
www.chordoma-uk.org

Chris Lucas Trust
www.chrislucastrust.com

Chronic Myeloid Leukaemia (CML) Support Group UK
www.cmlsupport.org.uk

CLIC Sargent Cancer Care for Children
www.clicsargent.org.uk

CLL Support Association
www.cllsupport.org.uk

Debbie Fund
www.debbiefund.org

DKMS
www.dkms.org.uk

EHE Rare Cancer Charity (UK)
www.ehercc.org.uk

Ellen MacArthur Cancer Trust
www.ellenmacarthurcancertrust.org

Fight Bladder Cancer
www.fightbladdercancer.co.uk

GIST Cancer UK
www.gistcancer.org.uk

GUTS Charity
www.gutscharity.org.uk

Guy Francis Bone Cancer Research Fund
www.gfbonecancer.org.uk

Heartburn Cancer UK
www.heartburncanceruk.org

HLRCC Family Alliance
www.hlrccinfo.org

ICPV Independent Cancer Patients' Voice
www.icpv.org.uk

International Brain Tumour Alliance (IBTA)
www.theibta.org

It's In The Bag Cancer Support Ltd
www.itsinthebag.org.uk

It's on the Ball
www.itsontheball.org

Jo's Cervical Cancer Trust
www.jostrust.org.uk

Kidney Cancer Support Network
www.kcsn.org.uk

Kidney Cancer UK
www.kcuk.org.uk

Leukaemia CARE
www.leukaemiacare.org.uk

Lymphoedema Support Network
www.lymphoedema.org

Lymphoma Action
www.lymphoma-action.org.uk

Maggie's Cancer Caring Centres
www.maggies.org

MDS (Myelodysplastic Syndromes) UK Patient Support Group
www.mdspatientsupport.org.uk

Melanoma Focus
www.melanomafocus.com

Mesothelioma UK
www.mesothelioma.uk.com

MPN Voice
www.mpnvoice.org.uk

Mummy's Star
www.mummysstar.org

My Name Is Not Cancer
www.mynamemiscancer.com

Myeloma UK
www.myeloma.org.uk

Neuroblastoma UK
www.neuroblastoma.org.uk

Neuroendocrine Cancer UK (NCEUK)
www.neuroendocrinecancer.org.uk

OcuMel UK
www.ocumeluk.org

Oracle Cancer Trust
www.oraclecancertrust.org

Orchid Cancer Appeal
www.orchid-cancer.org.uk

Ovacome, The Ovarian Cancer Support Network
www.ovacome.org.uk

Ovarian Cancer Action
www.ovarian.org.uk

Pancreatic Cancer Action
www.pancreaticcanceraction.org

Pancreatic Cancer UK (PCUK)
www.pancreaticcancer.org.uk

Pelvic Radiation Disease Association (PRDA)
www.prda.org.uk

PLANETS
www.planetscharity.org

Pseudomyxoma Survivor
www.pseudomyxomasurvivor.org

Rare Disease UK
www.raredisease.org.uk

Salivary Gland Cancer UK
www.salivaryglandcancer.uk

Sarcoma UK
www.sarcoma.org.uk

Shine Cancer Support
www.shinecancersupport.org

Solving Kids' Cancer
www.solvingkidscancer.org.uk

Target Ovarian Cancer
www.targetovariancancer.org.uk

Team Margot Foundation
www.teammargot.com

Teenage Cancer Trust (TCT)
www.teenagecancertrust.org

The Brain Tumour Charity
www.thebraintumourcharity.org

The Eve Appeal
www.eveappeal.org.uk

The Northern Ireland Rare Disease Partnership
www.nirdp.org.uk

The Robin Cancer Trust
www.therobincancertrust.org

Thyroid Cancer Support Group Wales
www.thyroidsupportwales.co.uk

Tom Bowdidge Youth Cancer Foundation
www.tombowdidgefoundation.org

Trekstock
www.trekstock.com

Urostomy Association
www.urostomyassociation.org.uk

VHL UK & Ireland
www.vhl-uk-ireland.org

Waldenstrom's Macroglobulinaemia (WMUK)
www.wmuk.org.uk

Wellbeing of Women
www.wellbeingofwomen.org.uk

Womb Cancer Info
www.wombcancerinfo.wixsite.com/home

Womb Cancer Support UK
www.wombcancersupportuk.weebly.com

Yorkshire Cancer Community
www.yorkshirecancercommunity.co.uk



Cancer52 is registered as a charity in England and Wales, **Charity No. 1174569** and as a company limited by guarantee in England and Wales, **Company No. 07994413**

If we **work together**
we can make as much noise as the big four

